Article
Oncology
Ali Ayhan, Safak Yilmaz Baran, Dogan Vatansever, Gulsen Dogan Durdag, Huseyin Akilli, Husnu Celik, Cagatay Taskiran
Summary: The study found that performing HIPEC during the COVID-19 pandemic is safe and feasible, with acceptable morbidity and mortality rates. Careful patient selection and precautions before the procedure are important to prevent infections and complications.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Soo Jin Park, Eun Ji Lee, Aeran Seol, Sunwoo Park, Jiyeon Ham, Ga Won Yim, Seung-Hyuk Shim, Whasun Lim, Suk-Joon Chang, Gwonhwa Song, Ji Won Park, Hee Seung Kim
Summary: Using paclitaxel and cisplatin in a novel prototype of rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) in a pig model showed higher tissue concentrations and lower serum concentrations. Paclitaxel had a longer absorption time into the bloodstream compared to cisplatin, with higher tissue-to-serum concentration ratios. No renal and hepatic toxicities were observed after RIPAC.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Review
Oncology
Julia H. Gelissen, Naomi N. Adjei, Blair McNamara, Levent Mutlu, Justin A. Harold, Mitchell Clark, Gary Altwerger, Peter R. Dottino, Gloria S. Huang, Alessandro D. Santin, Masoud Azodi, Elena Ratner, Peter E. Schwartz, Vaagn Andikyan
Summary: HIPEC is a treatment modality for ovarian cancer that combines intraperitoneal chemotherapy with hyperthermia during cytoreductive surgery to target tumor dissemination in the peritoneum. Currently, only cisplatin HIPEC after neoadjuvant chemotherapy is supported by high-quality evidence for stage III ovarian cancer. There are many unresolved questions regarding the timing and candidates for HIPEC, as well as the specifics of HIPEC protocols.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Anette Stolberg Kargo, Pernille Tine Jensen, Kristina Lindemann, Niels Henrik Hjollund, Gabor Istvan Liposits, Nicoline Raaschou-Jensen, Bettina Molri Knudsen, Soren Moller, Dorte Gilsa Hansen, Karina Dahl Steffensen
Summary: This study aimed to explore the diagnostic accuracy of repeated measurement of patient-reported outcomes and quality-of-life scores in relation to ovarian cancer recurrence. Results showed that despite the worsening of symptoms prior to recurrence, the patient-reported outcomes did not provide adequate diagnostic accuracy. Future efforts should focus on improving the administration of patient-reported outcomes and exploring their potential clinical relevance.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Katrin M. Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L. Friedlander
Summary: The study aimed to evaluate the effectiveness of intraperitoneal bevacizumab in delaying re-accumulation of malignant ascites in chemotherapy-resistant epithelial ovarian cancer patients. The results showed that IP-bev was safe, active, and could be considered as a palliative intervention for recurrent ascites.
GYNECOLOGIC ONCOLOGY
(2021)
Review
Oncology
Bryony Alderman, Lindsey Allan, Koji Amano, Carole Bouleuc, Mellar Davis, Stephanie Lister-Flynn, Sandip Mukhopadhyay, Andrew Davies
Summary: The provision of clinically assisted nutrition in patients with advanced cancer is controversial, with the Palliative Care Study Group of MASCC developing evidence-based guidance on its use. The outcomes include 11 suggestions and 1 recommendation, focusing on patient assessment, indications and contraindications for CAN, initiation procedures, and patient reassessment. This guidance offers a framework for CAN use in advanced cancer, emphasizing the need for individualized management for each patient.
SUPPORTIVE CARE IN CANCER
(2022)
Article
Oncology
Keely Krolikowski Ulmer, Breanna Greteman, Nicholas Cardillo, Anthony Schneider, Megan McDonald, David Bender, Michael J. Goodheart, Jesus Gonzalez Bosquet
Summary: This study found that patients with ovarian cancer living in rural areas with smaller populations and greater distance to tertiary care centers have poorer survival rates in the United States.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Nicolas Tabchouri, Jonathan Buggisch, Cedric Remy Demtroeder, Julien Thiery, Gunther Rezniczek, Clemens B. Tempfer, Britta Fischer, Can Dogan, Thierry Lecomte, Mehdi Ouaissi, Urs Giger-Pabst
Summary: The study demonstrated that repetitive pressurized intraperitoneal aerosol chemotherapy (PIPAC-Ox) for patients with non-resectable colorectal peritoneal metastases (CPM) is feasible, especially with three or more consecutive cycles showing improvement in survival rates.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Surgery
C. Bachmann, I Sautkin, G. Nadiradze, R. Archid, F. J. Weinreich, A. Koenigsrainer, M. A. Reymond
Summary: This study successfully developed a technology for applying pressurized intraperitoneal aerosol chemotherapy under hyperthermic conditions. By using a combination of industry-standard medical devices after modification, therapeutic hyperthermia could be established and chemotherapeutic drugs could be aerosolized in an ex-vivo model.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
(2021)
Article
Oncology
Lucas W. Thornblade, Ernest Han, Yuman Fong
Summary: Patients with colorectal cancer ovarian metastasis have favorable long-term survival. Survival rates are higher if the tumor is isolated to the ovary or if metachronous to the primary cancer.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2021)
Article
Oncology
Fatah Tidadini, Bertrand Trilling, Adeline Aime, Julio Abba, Jean-Louis Quesada, Alison Foote, Thierry Chevallier, Olivier Glehen, Jean -Luc Faucheron, Sihame Chkair, Catherine Arvieux
Summary: Pressurized Intraperitoneal Aerosol chemotherapy (PIPAC) is a new surgical technique for treating unresectable peritoneal carcinomatosis. This study estimated the mean cost of hospitalization for PIPAC in two French public teaching hospitals. The results showed that each PIPAC hospitalization cost the hospital an average of 2531 euros, while the fixed-rate remuneration was only 4031 euros.
Article
Biochemistry & Molecular Biology
Wei-Chun Chen, Huei-Jean Huang, Lan-Yan Yang, Yu-Bin Pan, Kuan-Gen Huang, Cheng-Tao Lin, Min-Yu Chen, Yun-Hsin Tang, Ting-Chang Chang, Chyong-Huey Lai, Hung-Hsueh Chou
Summary: Secondary cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has potential benefits for patients with recurrent ovarian cancer, with factors such as previous chemotherapy, chemotherapy-free interval, and CA125 levels before HIPEC contributing to prognosis. However, there are also associated toxicities.
BIOMEDICAL JOURNAL
(2022)
Article
Biotechnology & Applied Microbiology
Xiuyu Huang, Miaojuan Qiu, Tianqi Wang, Binbin Li, Shiqiang Zhang, Tianzhi Zhang, Peng Liu, Qiang Wang, Zhi Rong Qian, Chengming Zhu, Meiying Wu, Jing Zhao
Summary: This study introduces a novel self-assembly nanomedicine, ACaT, composed of alendronate, calcium ions, and cyclin-dependent kinase 7 (CDK7) inhibitor THZ1, which exhibited favorable tumor targeting, antitumor activity, and good biocompatibility. The ACaT nanoparticles were selectively internalized by tumor cells and effectively accumulated in the tumor site, promoting tumor cell apoptosis and inhibiting migration through affecting cell cycle, ROS levels, and calcium homeostasis. Weekly intraperitoneal administration of ACaT significantly suppressed tumor growth and improved survival in xenograft mice, demonstrating its potential as a therapeutic strategy for advanced ovarian cancer.
JOURNAL OF NANOBIOTECHNOLOGY
(2022)
Review
Oncology
Olivia G. Huffman, Danielle B. Chau, Andreea I. Dinicu, Robert DeBernardo, Ofer Reizes
Summary: This review examines the impact of hyperthermic intraperitoneal chemotherapy (HIPEC) on ovarian cancer and discusses its effects on the immune response, DNA damage, DNA damage repair pathways, and synergy with chemotherapy. It provides important insights for the development of new therapeutic strategies for ovarian cancer patients.
Article
Oncology
Xavier Fung, I. Chuan Li, Kandiah Chandrakumaran, Tom Cecil, Sanjeev Dayal, Alexios Tzivanakis, Brendan Moran, Faheez Mohamed
Summary: This study retrospectively analyzed data from a high-volume institution over a 25-year period on the use of early postoperative intraperitoneal chemotherapy (EPIC) for pseudomyxoma peritonei. The study found that EPIC treatment is a safe and effective option when used in carefully selected patients at a high-volume center.
Article
Obstetrics & Gynecology
Guenther A. Rezniczek, Julia M. Hecken, Sadia Rehman, Askin Dogan, Clemens B. Tempfer, Ziad Hilal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
(2020)
Letter
Rheumatology
Ioana Andreica, David Kiefer, Guenther A. Rezniczek, Robert Jast, Bjoern Buehring, Uta Kiltz, Xenofon Baraliakos, Juergen Braun
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Review
Oncology
Clemens B. Tempfer, Ziad Hilal, Peter Kern, Ingolf Juhasz-Boess, Guenther A. Rezniczek
Article
Biotechnology & Applied Microbiology
Moritz Anft, Krystallenia Paniskaki, Arturo Blazquez-Navarro, Adrian Doevelaar, Felix S. Seibert, Bodo Holzer, Sarah Skrzypczyk, Eva Kohut, Julia Kurek, Jan Zapka, Patrizia Wehler, Sviatlana Kaliszczyk, Sharon Bajda, Constantin J. Thieme, Toralf Roch, Margarethe Justine Konik, Marc Moritz Berger, Thorsten Brenner, Uwe Kolsch, Toni L. Meister, Stephanie Pfaender, Eike Steinmann, Clemens Tempfer, Carsten Watzl, Sebastian Dolff, Ulf Dittmer, Mohamed Abou-El-Enein, Timm H. Westhoff, Oliver Witzke, Ulrik Stervbo, Nina Babel
Review
Oncology
Thilo Dork, Peter Hillemanns, Clemens Tempfer, Julius Breu, Markus C. Fleisch
Article
Oncology
Gunther A. Rezniczek, Urs Giger-Pabst, Omar Thaher, Clemens B. Tempfer
Article
Oncology
Guenther A. Rezniczek, Jonathan Buggisch, Julien Sobilo, Alexandre Launay, Stephanie Lerondel, Alain Le Pape, Mehdi Ouaissi, Daniel Goehler, Metin Senkal, Urs Giger-Pabst, Clemens B. Tempfer
Meeting Abstract
Rheumatology
I. Andreica, R. Jast, G. Rezniczek, U. Kiltz, D. Kiefer, B. Buehring, X. Baraliakos, J. Braun
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Medicine, General & Internal
Gunther A. Rezniczek, Samira Ertan, Sadia Rehman, Clemens B. Tempfer
Summary: The study assessed the performance of Lugol's iodine test during colposcopy, showing moderate sensitivity and poor specificity for detecting LSIL/HSIL. However, it was found to change clinical management in 5% of cases, indicating potential utility in addition to acetic acid.
Article
Obstetrics & Gynecology
Guenther A. Rezniczek, Nadja Neghabian, Sadia Rehman, Clemens B. Tempfer
Summary: When performing Large Loop Excision of the Transformation Zone (LLETZ) for cervical dysplasia, video colposcopy and a headlight resulted in comparable resected cone mass. The video colposcopy group had shorter procedure time, less postoperative pain, but lower surgeon satisfaction.
ARCHIVES OF GYNECOLOGY AND OBSTETRICS
(2022)
Review
Oncology
Julia M. Hecken, Guenther A. Rezniczek, Clemens B. Tempfer
Summary: Cervical dysplasia is a common precancerous lesion that affects 1% to 2% of women worldwide. Significant progress has been made in the last decade in the diagnosis and treatment of cervical dysplasia. A systematic review of controlled clinical trials has led to specific and evidence-based recommendations for diagnostic and therapeutic interventions.